Achilles Therapeutics PLC Analysis

Achilles Stock Analysis Notes

About 83.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Achilles Therapeutics PLC recorded a loss per share of 1.66. The entity had not issued any dividends in recent years. Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Achilles Therapeutics PLC please contact Iraj Ali at 44 20 8154 4600 or go to https://www.achillestx.com.

Achilles Therapeutics PLC Investment Alerts

Achilles Therapeutics PLC Upcoming and Recent Events

Achilles Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.22 M.

Technical Drivers

As of the 27th of March, Achilles Therapeutics shows the mean deviation of 1.59, and Risk Adjusted Performance of 0.168. Achilles Therapeutics PLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Achilles Therapeutics PLC treynor ratio, and the relationship between the standard deviation and downside variance to decide if Achilles Therapeutics PLC is priced correctly, providing market reflects its regular price of 1.48 per share. Please also double-check Achilles Therapeutics PLC total risk alpha, which is currently at 0.6659 to validate the company can sustain itself at a future point.

Achilles Therapeutics PLC Price Movement Analysis

Achilles Therapeutics Outstanding Bonds

Achilles Therapeutics Predictive Daily Indicators

Achilles Therapeutics Forecast Models

Achilles Therapeutics' time-series forecasting models are one of many Achilles Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Achilles Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Achilles Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Achilles shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Achilles Therapeutics. By using and applying Achilles Stock analysis, traders can create a robust methodology for identifying Achilles entry and exit points for their positions.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

If you are still planning to invest in Achilles Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achilles Therapeutics' history and understand the potential risks before investing.